Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA

Autor: Lucas G. Hill, Mandy L Renfro, Claire M. Zagorski, Kirk E. Evoy, Joshua C. Perez, Shaun M. Jones, Lindsey J. Loera, Kelly R. Reveles, Sorina B. Torrez
Rok vydání: 2020
Předmět:
Zdroj: Addiction
ISSN: 1360-0443
0965-2140
DOI: 10.1111/add.15314
Popis: BACKGROUND AND AIMS Patients with opioid use disorder (OUD) must be able to obtain prescribed buprenorphine/naloxone films (BUP/NX) and naloxone nasal spray (NNS) from a pharmacy promptly to reduce risk for a recurrence of use and subsequent morbidity and mortality. Telephone audits have identified concerning gaps in availability of NNS within US pharmacies, but the availability of BUP/NX has not been rigorously evaluated. This study estimated the availability of BUP/NX and NNS in the US state of Texas and compared availability by pharmacy type and metropolitan status. DESIGN A cross-sectional telephone audit with a secret shopper approach conducted from 18 May 2020 to 7 June 2020. Setting and Participants A random sample of 800 of 5078 (16%) community pharmacies licensed with the Texas State Board of Pharmacy. MEASUREMENTS Primary outcomes included availability of a 1-week supply of generic BUP/NX 8/2 mg films and a single unit of NNS 4 mg, overall and by pharmacy type. Secondary outcomes included willingness and estimated time-frame to order BUP/NX if unavailable. FINDINGS Data from 704 pharmacies (471 chain, 233 independent) were included for analyses. Of these, 34.1% of pharmacies (45.0% of chains versus 12.0% of independents, P
Databáze: OpenAIRE
Externí odkaz: